DOCSLIB.ORG

Supplementary Table S2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Table S2 Table 2 HIF-1 target genes Unigene ID Hyp/Norm Name Name Hs.296323 0.50 SGK serum/glucocorticoid regulated kinase Hs.1048 0.53 KITLG KIT ligand Hs.1048 0.53 KITLG KIT ligand Hs.171723 0.55 TAF9L TAF9-like RNA polymerase II, TATA box binding protein Hs.374524 0.55 DHX9 DEAH (Asp-Glu-Ala-His) box polypeptide 9 Hs.21486 0.56 STAT1 signal transducer and activator of transcription 1, 91kDa Hs.390504 0.57 SOS2 son of sevenless homolog 2 (Drosophila) Hs.2227 0.57 CEBPG CCAAT/enhancer binding protein (C/EBP), gamma Hs.464526 0.58 ABHD3 abhydrolase domain containing 3 Hs.107056 0.60 CED-6 PTB domain adaptor protein CED-6 Hs.417157 0.61 MGC14376 hypothetical protein MGC14376 Hs.201939 0.61 ATP6V0A2 ATPase, H+ transporting, lysosomal V0 subunit a isoform 2 Hs.7879 0.61 IFRD1 interferon-related developmental regulator 1 Hs.25204 0.61 CHST12 carbohydrate (chondroitin 4) sulfotransferase 12 Hs.58617 0.62 ROCK2 Rho-associated, coiled-coil containing protein kinase 2 Hs.477132 0.62 COPA coatomer protein complex, subunit alpha Hs.389893 0.62 DLG1 discs, large homolog 1 (Drosophila) Hs.439052 0.63 SPIN spindlin Hs.334534 0.63 GNS glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease IIID) Hs.459631 0.63 Homo sapiens cDNA FLJ12835 fis, clone NT2RP2003165. Hs.336425 0.63 Homo sapiens mRNA; cDNA DKFZp313P052 Hs.17969 0.64 KIAA0663 KIAA0663 gene product Hs.28578 0.65 MBNL1 muscleblind-like (Drosophila) Hs.55220 0.65 BAG2 BCL2-associated athanogene 2 Hs.143840 0.65 KIAA0852 KIAA0852 protein Hs.432996 0.66 FLJ12448 hypothetical protein FLJ12448 Hs.159118 0.66 AMD1 adenosylmethionine decarboxylase 1 Hs.443409 0.67 ODC1 ornithine decarboxylase 1 Hs.153648 79.51 PPFIA4 protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF) Hs.9613 13.36 ANGPTL4 angiopoietin-like 4 Hs.433611 13.29 PDK1 pyruvate dehydrogenase kinase, isoenzyme 1 Hs.511915 11.12 ENO2 enolase 2, (gamma, neuronal) Hs.441047 10.84 ADM adrenomedullin Hs.283844 10.16 BA108L7.2 similar to rat tricarboxylate carrier-like protein Hs.171825 9.91 BHLHB2 basic helix-loop-helix domain containing, class B, 2 Hs.318567 9.21 NDRG1 N-myc downstream regulated gene 1 Hs.198278 8.36 PFKFB4 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 Hs.437647 6.94 FLJ10415 hypothetical protein FLJ10415 Hs.27744 6.65 RAB3A RAB3A, member RAS oncogene family Hs.79428 6.29 BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3 Hs.467262 5.74 PTRF polymerase I and transcript release factor Hs.10862 5.47 AK3 adenylate kinase 3 Hs.123159 5.41 SPAG4 sperm associated antigen 4 Hs.155247 5.14 ALDOC aldolase C, fructose-bisphosphate Hs.79428 5.12 BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3 Hs.171825 4.88 BHLHB2 basic helix-loop-helix domain containing, class B, 2 Hs.132955 4.51 BNIP3L BCL2/adenovirus E1B 19kDa interacting protein 3-like Hs.7089 4.37 INSIG2 insulin induced gene 2 Hs.10949 4.34 ERO1L ERO1-like (S. cerevisiae) Hs.10862 4.28 AK3 adenylate kinase 3 Hs.96028 4.23 FOXD1 forkhead box D1 Hs.462911 4.21 NOL3 nucleolar protein 3 (apoptosis repressor with CARD domain) Hs.443452 4.12 PMX1 paired mesoderm homeo box 1 Hs.195471 4.12 PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 Hs.61762 3.80 HIG2 hypoxia-inducible protein 2 Hs.462911 3.72 NOL3 nucleolar protein 3 (apoptosis repressor with CARD domain) Hs.73793 3.47 VEGF vascular endothelial growth factor Hs.104800 3.43 FLJ10134 hypothetical protein FLJ10134 Hs.118630 3.28 MXI1 MAX interacting protein 1 Hs.32352 3.23 DKFZp434K1210 hypothetical protein DKFZp434K1210 Hs.289007 3.21 FLJ10803 hypothetical protein FLJ10803 Hs.37054 3.14 EFNA3 ephrin-A3 Hs.1869 3.04 PGM1 phosphoglucomutase 1 Hs.73793 3.00 VEGF vascular endothelial growth factor Hs.5243 2.99 E2IG5 growth and transformation-dependent protein Hs.132955 2.99 BNIP3L BCL2/adenovirus E1B 19kDa interacting protein 3-like Hs.111244 2.86 RTP801 HIF-1 responsive RTP801 Hs.511986 2.85 GBE1 glucan (1,4-alpha-), branching enzyme 1 Hs.303090 2.85 PPP1R3C protein phosphatase 1, regulatory (inhibitor) subunit 3C Hs.321707 2.80 JMJD1 jumonji domain containing 1 Hs.274317 2.78 DDX41 DEAD (Asp-Glu-Ala-Asp) box polypeptide 41 Hs.274485 2.78 HLA-C major histocompatibility complex, class I, C Hs.444594 2.74 LOC283849 hypothetical protein LOC283849 Hs.27410 2.71 PBF papillomavirus regulatory factor PRF-1 Hs.498489 2.70 PFKP phosphofructokinase, platelet Hs.76768 2.65 P4HA1 procollagen-proline, 2-oxoglutarate 4-dioxygenase) Hs.32393 2.62 DARS aspartyl-tRNA synthetase Hs.198281 2.62 PKM2 pyruvate kinase, muscle Hs.25590 2.61 STC1 stanniocalcin 1 Hs.363315 2.61 B3GNT4 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 4 Hs.371366 2.57 APS adaptor protein with pleckstrin homology and src homology 2 Hs.515218 2.57 7h3 hypothetical protein FLJ13511 Hs.63304 2.56 PME-1 protein phosphatase methylesterase-1 Hs.73793 2.56 VEGF vascular endothelial growth factor Hs.386225 2.54 GYS1 glycogen synthase 1 (muscle) Hs.406266 2.53 HK2 hexokinase 2 Hs.315379 2.51 WSB1 SOCS box-containing WD protein SWiP-1 Hs.110571 2.49 GADD45B growth arrest and DNA-damage-inducible, beta Hs.104772 2.47 P4HA2 procollagen-proline, 2-oxoglutarate 4-dioxygenase) Hs.25590 2.46 STC1 stanniocalcin 1 Hs.110571 2.43 GADD45B growth arrest and DNA-damage-inducible, beta Hs.318127 2.42 FLJ10201 hypothetical protein FLJ10201 Hs.45743 2.35 ADORA2B adenosine A2b receptor Hs.238679 2.35 RRAGD Ras-related GTP binding D Hs.155223 2.34 STC2 stanniocalcin 2 Hs.109590 2.33 GENX-3414 genethonin 1 Hs.448341 2.32 ZNF292 zinc finger protein 292 Hs.143323 2.31 PLU-1 putative DNA/chromatin binding motif Hs.315379 2.30 WSB1 SOCS box-containing WD protein SWiP-1 Hs.3416 2.28 ADFP adipose differentiation-related protein Hs.150555 2.27 HSU79274 protein predicted by clone 23733 Hs.4082 2.26 LGALS8 lectin, galactoside-binding, soluble, 8 (galectin 8) Hs.315379 2.25 WSB1 SOCS box-containing WD protein SWiP-1 Hs.78771 2.25 PGK1 phosphoglycerate kinase 1 Hs.78771 2.25 PGK1 phosphoglycerate kinase 1 Hs.226007 2.25 RDH11 retinol dehydrogenase 11 (all-trans and 9-cis) Hs.213289 2.25 LDLR low density lipoprotein receptor (familial hypercholesterolemia) Hs.154396 2.24 CT120 membrane protein expressed in epithelial-like lung adenocarcinoma Hs.25590 2.23 STC1 stanniocalcin 1 Hs.77961 2.16 HLA-B major histocompatibility complex, class I, B Hs.28988 2.16 GLRX glutaredoxin (thioltransferase) Hs.2795 2.14 LDHA lactate dehydrogenase A Hs.388170 2.12 FLJ10534 hypothetical protein FLJ10534 Hs.512813 2.11 SAP30 sin3-associated polypeptide, 30kDa Hs.7277 2.11 PEX3 peroxisomal biogenesis factor 3 Hs.352733 2.09 PAM peptidylglycine alpha-amidating monooxygenase Hs.179791 2.09 RAB20 RAB20, member RAS oncogene family Hs.78781 2.08 VEGFB vascular endothelial growth factor B Hs.143323 2.08 PLU-1 putative DNA/chromatin binding motif Hs.7277 2.03 PEX3 peroxisomal biogenesis factor 3 Hs.443906 2.02 EGLN3 egl nine homolog 3 (C. elegans) Hs.118893 2.01 D2S448 Melanoma associated gene Hs.147747 2.01 HOXA4 homeo box A4 Hs.274485 2.00 HLA-C major histocompatibility complex, class I, C Hs.72222 1.98 FER1L4 fer-1-like 4 (C. elegans) Hs.508741 1.97 C5orf13 chromosome 5 open reading frame 13 Hs.256526 1.97 NARF nuclear prelamin A recognition factor Hs.102929 1.95 AF3P21 SH3 protein interacting with Nck, 90 kDa Hs.75694 1.95 MPI mannose phosphate isomerase Hs.441069 1.95 MIZ1 Msx-interacting-zinc finger Hs.51 1.94 PIGA phosphatidylinositol glycan, class A Hs.35380 1.93 BBX bobby sox homolog (Drosophila) Hs.78979 1.93 GLG1 golgi apparatus protein 1 Hs.75199 1.93 PPP2R5B protein phosphatase 2, regulatory subunit B (B56), beta isoform Hs.512813 1.93 SAP30 sin3-associated polypeptide, 30kDa Hs.9291 1.92 7h3 hypothetical protein FLJ13511 Hs.274579 1.92 CNNM1 cyclin M1 Hs.83469 1.92 NFE2L1 nuclear factor (erythroid-derived 2)-like 1 Hs.211600 1.91 TNFAIP3 tumor necrosis factor, alpha-induced protein 3 Hs.315379 1.91 WSB1 SOCS box-containing WD protein SWiP-1 Hs.55565 1.90 ANKRD3 ankyrin repeat domain 3 Hs.13321 1.90 RLF rearranged L-myc fusion sequence Hs.130316 1.90 MGC10772 hypothetical protein MGC10772 Hs.77266 1.89 QSCN6 quiescin Q6 Hs.155223 1.89 STC2 stanniocalcin 2 Hs.324844 1.89 IMAGE3455200 hypothetical protein IMAGE3455200 Hs.20644 1.89 BCKDK branched chain alpha-ketoacid dehydrogenase kinase Hs.512152 1.86 HLA-G HLA-G histocompatibility antigen, class I, G Hs.77768 1.86 DNAJB2 DnaJ (Hsp40) homolog, subfamily B, member 2 Hs.101174 1.85 MAPT microtubule-associated protein tau Hs.308026 1.85 HLA-DRB3 major histocompatibility complex, class II, DR beta 3 Hs.150136 1.85 MAPK7 mitogen-activated protein kinase 7 Hs.77961 1.84 HLA-B major histocompatibility complex, class I, B Hs.83469 1.84 NFE2L1 nuclear factor (erythroid-derived 2)-like 1 Hs.130946 1.84 EGLN1 egl nine homolog 1 (C. elegans) Hs.274485 1.83 HLA-C major histocompatibility complex, class I, C Hs.512152 1.82 HLA-G HLA-G histocompatibility antigen, class I, G Hs.211773 1.81 CHES1 checkpoint suppressor 1 Hs.352733 1.81 PAM peptidylglycine alpha-amidating monooxygenase Hs.179312 1.80 SNAPC1 small nuclear RNA activating complex, polypeptide 1, 43kDa Hs.142076 1.80 LOC91373 hypothetical protein LOC91373 Hs.9071 1.80 PGRMC2 progesterone receptor membrane component 2 Hs.356537 1.80 DAAM1 dishevelled associated activator of morphogenesis 1 Hs.448341 1.79 ZNF292 zinc finger protein 292 Hs.110488 1.79 CHSY1 carbohydrate (chondroitin) synthase 1 Hs.279843 1.79 MLH3 mutL homolog 3 (E.
Load more

Recommended publications
  • Dynamin Functions and Ligands: Classical Mechanisms Behind
    1521-0111/91/2/123–134$25.00 http://dx.doi.org/10.1124/mol.116.105064 MOLECULAR PHARMACOLOGY Mol Pharmacol 91:123–134, February 2017 Copyright ª 2017 by The American Society for Pharmacology and Experimental Therapeutics MINIREVIEW Dynamin Functions and Ligands: Classical Mechanisms Behind Mahaveer Singh, Hemant R. Jadhav, and Tanya Bhatt Department of Pharmacy, Birla Institute of Technology and Sciences Pilani, Pilani Campus, Rajasthan, India Received May 5, 2016; accepted November 17, 2016 Downloaded from ABSTRACT Dynamin is a GTPase that plays a vital role in clathrin-dependent pathophysiology of various disorders, such as Alzheimer’s disease, endocytosis and other vesicular trafficking processes by acting Parkinson’s disease, Huntington’s disease, Charcot-Marie-Tooth as a pair of molecular scissors for newly formed vesicles originating disease, heart failure, schizophrenia, epilepsy, cancer, dominant ’ from the plasma membrane. Dynamins and related proteins are optic atrophy, osteoporosis, and Down s syndrome. This review is molpharm.aspetjournals.org important components for the cleavage of clathrin-coated vesicles, an attempt to illustrate the dynamin-related mechanisms involved phagosomes, and mitochondria. These proteins help in organelle in the above-mentioned disorders and to help medicinal chemists division, viral resistance, and mitochondrial fusion/fission. Dys- to design novel dynamin ligands, which could be useful in the function and mutations in dynamin have been implicated in the treatment of dynamin-related disorders. Introduction GTP hydrolysis–dependent conformational change of GTPase dynamin assists in membrane fission, leading to the generation Dynamins were originally discovered in the brain and identi- of endocytic vesicles (Praefcke and McMahon, 2004; Ferguson at ASPET Journals on September 23, 2021 fied as microtubule binding partners.
    [Show full text]
  • Targeted Genes and Methodology Details for Neuromuscular Genetic Panels
    Targeted Genes and Methodology Details for Neuromuscular Genetic Panels Reference transcripts based on build GRCh37 (hg19) interrogated by Neuromuscular Genetic Panels Next-generation sequencing (NGS) and/or Sanger sequencing is performed Motor Neuron Disease Panel to test for the presence of a mutation in these genes. Gene GenBank Accession Number Regions of homology, high GC-rich content, and repetitive sequences may ALS2 NM_020919 not provide accurate sequence. Therefore, all reported alterations detected ANG NM_001145 by NGS are confirmed by an independent reference method based on laboratory developed criteria. However, this does not rule out the possibility CHMP2B NM_014043 of a false-negative result in these regions. ERBB4 NM_005235 Sanger sequencing is used to confirm alterations detected by NGS when FIG4 NM_014845 appropriate.(Unpublished Mayo method) FUS NM_004960 HNRNPA1 NM_031157 OPTN NM_021980 PFN1 NM_005022 SETX NM_015046 SIGMAR1 NM_005866 SOD1 NM_000454 SQSTM1 NM_003900 TARDBP NM_007375 UBQLN2 NM_013444 VAPB NM_004738 VCP NM_007126 ©2018 Mayo Foundation for Medical Education and Research Page 1 of 14 MC4091-83rev1018 Muscular Dystrophy Panel Muscular Dystrophy Panel Gene GenBank Accession Number Gene GenBank Accession Number ACTA1 NM_001100 LMNA NM_170707 ANO5 NM_213599 LPIN1 NM_145693 B3GALNT2 NM_152490 MATR3 NM_199189 B4GAT1 NM_006876 MYH2 NM_017534 BAG3 NM_004281 MYH7 NM_000257 BIN1 NM_139343 MYOT NM_006790 BVES NM_007073 NEB NM_004543 CAPN3 NM_000070 PLEC NM_000445 CAV3 NM_033337 POMGNT1 NM_017739 CAVIN1 NM_012232 POMGNT2
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Conserved and Novel Properties of Clathrin-Mediated Endocytosis in Dictyostelium Discoideum" (2012)
    Rockefeller University Digital Commons @ RU Student Theses and Dissertations 2012 Conserved and Novel Properties of Clathrin- Mediated Endocytosis in Dictyostelium Discoideum Laura Macro Follow this and additional works at: http://digitalcommons.rockefeller.edu/ student_theses_and_dissertations Part of the Life Sciences Commons Recommended Citation Macro, Laura, "Conserved and Novel Properties of Clathrin-Mediated Endocytosis in Dictyostelium Discoideum" (2012). Student Theses and Dissertations. Paper 163. This Thesis is brought to you for free and open access by Digital Commons @ RU. It has been accepted for inclusion in Student Theses and Dissertations by an authorized administrator of Digital Commons @ RU. For more information, please contact [email protected]. CONSERVED AND NOVEL PROPERTIES OF CLATHRIN- MEDIATED ENDOCYTOSIS IN DICTYOSTELIUM DISCOIDEUM A Thesis Presented to the Faculty of The Rockefeller University in Partial Fulfillment of the Requirements for the degree of Doctor of Philosophy by Laura Macro June 2012 © Copyright by Laura Macro 2012 CONSERVED AND NOVEL PROPERTIES OF CLATHRIN- MEDIATED ENDOCYTOSIS IN DICTYOSTELIUM DISCOIDEUM Laura Macro, Ph.D. The Rockefeller University 2012 The protein clathrin mediates one of the major pathways of endocytosis from the extracellular milieu and plasma membrane. Clathrin functions with a network of interacting accessory proteins, one of which is the adaptor complex AP-2, to co-ordinate vesicle formation. Disruption of genes involved in clathrin-mediated endocytosis causes embryonic lethality in multicellular animals suggesting that clathrin-mediated endocytosis is a fundamental cellular process. However, loss of clathrin-mediated endocytosis genes in single cell eukaryotes, such as S.cerevisiae (yeast), does not cause lethality, suggesting that clathrin may convey specific advantages for multicellularity.
    [Show full text]
  • Genome-Wide Analysis of Androgen Receptor Binding and Gene Regulation in Two CWR22-Derived Prostate Cancer Cell Lines
    Endocrine-Related Cancer (2010) 17 857–873 Genome-wide analysis of androgen receptor binding and gene regulation in two CWR22-derived prostate cancer cell lines Honglin Chen1, Stephen J Libertini1,4, Michael George1, Satya Dandekar1, Clifford G Tepper 2, Bushra Al-Bataina1, Hsing-Jien Kung2,3, Paramita M Ghosh2,3 and Maria Mudryj1,4 1Department of Medical Microbiology and Immunology, University of California Davis, 3147 Tupper Hall, Davis, California 95616, USA 2Division of Basic Sciences, Department of Biochemistry and Molecular Medicine, Cancer Center and 3Department of Urology, University of California Davis, Sacramento, California 95817, USA 4Veterans Affairs Northern California Health Care System, Mather, California 95655, USA (Correspondence should be addressed to M Mudryj at Department of Medical Microbiology and Immunology, University of California, Davis; Email: [email protected]) Abstract Prostate carcinoma (CaP) is a heterogeneous multifocal disease where gene expression and regulation are altered not only with disease progression but also between metastatic lesions. The androgen receptor (AR) regulates the growth of metastatic CaPs; however, sensitivity to androgen ablation is short lived, yielding to emergence of castrate-resistant CaP (CRCaP). CRCaP prostate cancers continue to express the AR, a pivotal prostate regulator, but it is not known whether the AR targets similar or different genes in different castrate-resistant cells. In this study, we investigated AR binding and AR-dependent transcription in two related castrate-resistant cell lines derived from androgen-dependent CWR22-relapsed tumors: CWR22Rv1 (Rv1) and CWR-R1 (R1). Expression microarray analysis revealed that R1 and Rv1 cells had significantly different gene expression profiles individually and in response to androgen.
    [Show full text]
  • Myopathy Genes (HGNC) Neuropathy (HGNC) Neuromuscular Disease
    Myopathy Genes Neuropathy Neuromuscular Disease (HGNC) (HGNC) (HGNC) ABHD5 ABCA1 ADCK3 ACTG2 ACO2 AGRN AGK AGXT ALS2 ALDOA AIFM1 ANG AMER1 ALAD AP4B1 ANO5 AMACR AP4E1 AR AP1S1 AP4M1 AUH APTX AP4S1 B4GALT1 AR AP5Z1 CACNA1S ATL3 ATM CASQ1 B4GALNT1 ATXN10 CCDC78 BAG3 ATXN7 CHCHD10 BRP44L BEAN1 CHRNA1 C12orf65 C9orf72 CHRNB1 C19orf12 CACNB4 CHRND C1NH CAPN3 CHRNE CECR1 CHAT CLPB CISD2 CHKB COL6A1 CLCF1 CHMP2B COL6A2 CLCN2 CHRNG COL6A3 CLP1 CLCN1 COLQ CMT2G COL9A3 CTNS CMT2H COQ2 DGUOK CMTDIA COQ6 DNA2 CMTX2 COQ9 DNAJB6 CMTX3 COX15 DNAJC19 COASY CPT1A DNM2 COX6A1 CYP7B1 DPM2 CPOX DAG1 DYSF CYP27A1 DDHD2 EMD CYP2U1 DOK7 EPG5 DARS2 DPAGT1 FAM111B DCAF8 DPM3 FBXL4 DDHD1 DUX4 FKBP14 DFNX5 ECEL1 FKRP DHTKD1 ERBB3 FLH1 DIAPH3 ERLIN2 FLNC DNAJB2 FA2H HNRNPA1 DNAJC3 FKTN HNRNPDL ELOVL5 FUS HNRPA2B1 ERCC8 G6PC KLHL40 FAH GFPT1 KLHL41 FAM126A GLE1 LAMA2 FBN1 GYS2 LDB3 FMR1 HSPD1 LMOD3 FXN IFRD1 MEGF10 GALC INF2 MGME1 GBE1 ISPD MTAP GJC2 ITGA7 MTMR14 GP1BA ITPR1 MYF6 HADHA KCNA1 MYH14 HADHB KCNC3 MYLK2 HFE KCNE3 NARS2 HINT1 KCNJ18 NEB HK1 KCNJ2 ORAI1 HMBS KIAA0196 PRKAG2 HSD17B4 KIF21A PTEN HSN1B L1CAM RBCK1 IARS2 LAMB2 RET IGHMBP2 LARGE RMND1 KCNJ10 MCCC2 SCN4A KIF5A MRE11A SERAC1 LRSAM1 MRPL3 SGCA LYST MTO1 SIL1 MANBA MTPAP SPEG MARS MTTP STAC3 MTATP6 MUSK STIM1 MYH14 MYBPC3 SYNE1 MYOT MYH3 SYNE2 NAMSD MYH8 TAZ NF2 NF1 TIA1 NGLY1 NIPA1 TMEM43 NMSR NOP56 TNPO3 NOTCH3 OPTN TNXB OPA1 PDSS2 TPM2 OPA3 PDYN TRPV4 OTOF PFN1 UBA1 PDK3 PHKA2 VCP PDSS1 PHKG2 XDH PEX10 PHOX2A ACADS PEX2 PIP5K1C ACADVL PMM2 PLEC ACTA1 PNPLA6 PLP1 AGL PPOX POMGNT1 AMPD1 PRICKLE1
    [Show full text]
  • Ncomms4301.Pdf
    ARTICLE Received 8 Jul 2013 | Accepted 23 Jan 2014 | Published 13 Feb 2014 DOI: 10.1038/ncomms4301 Genome-wide RNAi ionomics screen reveals new genes and regulation of human trace element metabolism Mikalai Malinouski1,2, Nesrin M. Hasan3, Yan Zhang1,4, Javier Seravalli2, Jie Lin4,5, Andrei Avanesov1, Svetlana Lutsenko3 & Vadim N. Gladyshev1 Trace elements are essential for human metabolism and dysregulation of their homoeostasis is associated with numerous disorders. Here we characterize mechanisms that regulate trace elements in human cells by designing and performing a genome-wide high-throughput siRNA/ionomics screen, and examining top hits in cellular and biochemical assays. The screen reveals high stability of the ionomes, especially the zinc ionome, and yields known regulators and novel candidates. We further uncover fundamental differences in the regulation of different trace elements. Specifically, selenium levels are controlled through the selenocysteine machinery and expression of abundant selenoproteins; copper balance is affected by lipid metabolism and requires machinery involved in protein trafficking and post-translational modifications; and the iron levels are influenced by iron import and expression of the iron/haeme-containing enzymes. Our approach can be applied to a variety of disease models and/or nutritional conditions, and the generated data set opens new directions for studies of human trace element metabolism. 1 Genetics Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA. 2 Department of Biochemistry, University of Nebraska-Lincoln, Lincoln, Nebraska 68588, USA. 3 Department of Physiology, Johns Hopkins University, Baltimore, Maryland 21205, USA. 4 Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China.
    [Show full text]
  • PRODUCT SPECIFICATION Prest Antigen PNRC1 Product
    PrEST Antigen PNRC1 Product Datasheet PrEST Antigen PRODUCT SPECIFICATION Product Name PrEST Antigen PNRC1 Product Number APrEST77609 Gene Description proline-rich nuclear receptor coactivator 1 Alternative Gene B4-2, PROL2, PRR2 Names Corresponding Anti-PNRC1 (HPA029839) Antibodies Description Recombinant protein fragment of Human PNRC1 Amino Acid Sequence Recombinant Protein Epitope Signature Tag (PrEST) antigen sequence: QLVHGIHLYEQPKINRQKSKYNLPLTKITSAKRNENNFWQDSVSSDRIQK QEKKPFKNTENIKNSHLKKSAFLTEVSQKENYAGAKFSDPPSPSVLPK Fusion Tag N-terminal His6ABP (ABP = Albumin Binding Protein derived from Streptococcal Protein G) Expression Host E. coli Purification IMAC purification Predicted MW 29 kDa including tags Usage Suitable as control in WB and preadsorption assays using indicated corresponding antibodies. Purity >80% by SDS-PAGE and Coomassie blue staining Buffer PBS and 1M Urea, pH 7.4. Unit Size 100 µl Concentration Lot dependent Storage Upon delivery store at -20°C. Avoid repeated freeze/thaw cycles. Notes Gently mix before use. Optimal concentrations and conditions for each application should be determined by the user. Product of Sweden. For research use only. Not intended for pharmaceutical development, diagnostic, therapeutic or any in vivo use. No products from Atlas Antibodies may be resold, modified for resale or used to manufacture commercial products without prior written approval from Atlas Antibodies AB. Warranty: The products supplied by Atlas Antibodies are warranted to meet stated product specifications and to conform to label descriptions when used and stored properly. Unless otherwise stated, this warranty is limited to one year from date of sales for products used, handled and stored according to Atlas Antibodies AB's instructions. Atlas Antibodies AB's sole liability is limited to replacement of the product or refund of the purchase price.
    [Show full text]
  • Molecular Interactions Underpinning the Phenotype of Hibernation in Mammals Matthew T
    © 2019. Published by The Company of Biologists Ltd | Journal of Experimental Biology (2019) 222, jeb160606. doi:10.1242/jeb.160606 REVIEW Molecular interactions underpinning the phenotype of hibernation in mammals Matthew T. Andrews* ABSTRACT most mammals. This Review covers recent advances in the Mammals maintain a constant warm body temperature, facilitating a molecular biology of hibernation, with a focus on molecular wide variety of metabolic reactions. Mammals that hibernate have the interactions underpinning the hibernation phenotype. Specific – ability to slow their metabolism, which in turn reduces their body topics include the torpor arousal cycle, the role of small temperature and leads to a state of hypothermic torpor. For this molecules, changes in gene expression, cold-inducible RNA- metabolic rate reduction to occur on a whole-body scale, molecular binding proteins, the somatosensory system and emerging interactions that change the physiology of cells, tissues and organs information on hibernating primates. This new information not are required, resulting in a major departure from normal mammalian only is beginning to explain how natural hibernators survive homeostasis. The aim of this Review is to cover recent advances in the physiological extremes that would be lethal to most mammals, but molecular biology of mammalian hibernation, including the role of also identifies molecular mechanisms that may prove useful to small molecules, seasonal changes in gene expression, cold- human medicine. inducible RNA-binding proteins,
    [Show full text]
  • PTEN Deficiency Causes Dyschondroplasia in Mice By
    DEVELOPMENT AND DISEASE RESEARCH ARTICLE 3587 Development 135, 3587-3597 (2008) doi:10.1242/dev.028118 PTEN deficiency causes dyschondroplasia in mice by enhanced hypoxia-inducible factor 1α signaling and endoplasmic reticulum stress Guan Yang, Qiang Sun, Yan Teng, Fangfei Li, Tujun Weng and Xiao Yang* Chondrocytes within the growth plates acclimatize themselves to a variety of stresses that might otherwise disturb cell fate. The tumor suppressor PTEN (phosphatase and tensin homolog deleted from chromosome 10) has been implicated in the maintenance of cell homeostasis. However, the functions of PTEN in regulating chondrocytic adaptation to stresses remain largely unknown. In this study, we have created chondrocyte-specific Pten knockout mice (Ptenco/co;Col2a1-Cre) using the Cre-loxP system. Following AKT activation, Pten mutant mice exhibited dyschondroplasia resembling human enchondroma. Cartilaginous nodules originated from Pten mutant resting chondrocytes that suffered from impaired proliferation and differentiation, and this was coupled with enhanced endoplasmic reticulum (ER) stress. We further found that ER stress in Pten mutant chondrocytes only occurred under hypoxic stress, characterized by an upregulation of unfolded protein response-related genes as well as an engorged and fragmented ER in which collagens were trapped. An upregulation of hypoxia-inducible factor 1α (HIF1α) and downstream targets followed by ER stress induction was also observed in Pten mutant growth plates and in cultured chondrocytes, suggesting that PI3K/AKT
    [Show full text]
  • Anti-PGK1 + PGK2 Antibody (ARG40834)
    Product datasheet [email protected] ARG40834 Package: 50 μg anti-PGK1 + PGK2 antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes PGK1 + PGK2 Tested Reactivity Hu, Rat Predict Reactivity Ms, Hm Tested Application IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name PGK1 + PGK2 Antigen Species Human Immunogen Synthetic peptide corresponding to aa. 166-180 of Human PGK1. (FGTAHRAHSSMVGVN) Conjugation Un-conjugated Alternate Names EC 2.7.2.3; Primer recognition protein 2; PGKA; PRP 2; Phosphoglycerate kinase 1; MIG10; Cell migration-inducing gene 10 protein; HEL-S-68p Application Instructions Application table Application Dilution IHC-P 1:200 - 1:1000 WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 45 kDa Properties Form Liquid Purification Affinity purification with immunogen. Buffer 0.2% Na2HPO4, 0.9% NaCl, 0.05% Thimerosal, 0.05% Sodium azide and 5% BSA. Preservative 0.05% Thimerosal and 0.05% Sodium azide Stabilizer 5% BSA Concentration 0.5 mg/ml Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. www.arigobio.com 1/2 Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol PGK1 Gene Full Name phosphoglycerate kinase 1 Background The protein encoded by this gene is a glycolytic enzyme that catalyzes the conversion of 1,3-diphosphoglycerate to 3-phosphoglycerate.
    [Show full text]
  • Anti-PGK1 Antibody (ARG40844)
    Product datasheet [email protected] ARG40844 Package: 50 μg anti-PGK1 antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes PGK1 Tested Reactivity Hu, Rat Tested Application WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name PGK1 Antigen Species Human Immunogen Synthetic peptide corresponding to aa. 312-337 of Human PGK1. (MGLDCGPESSKKYAEAVTRAKQIVWN) Conjugation Un-conjugated Alternate Names EC 2.7.2.3; Primer recognition protein 2; PGKA; PRP 2; Phosphoglycerate kinase 1; MIG10; Cell migration-inducing gene 10 protein; HEL-S-68p Application Instructions Application table Application Dilution WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 45 kDa Properties Form Liquid Purification Affinity purification with immunogen. Buffer 0.2% Na2HPO4, 0.9% NaCl, 0.05% Sodium azide and 5% BSA. Preservative 0.05% Sodium azide Stabilizer 5% BSA Concentration 0.5 mg/ml Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. www.arigobio.com 1/2 Bioinformation Gene Symbol PGK1 Gene Full Name phosphoglycerate kinase 1 Background The protein encoded by this gene is a glycolytic enzyme that catalyzes the conversion of 1,3-diphosphoglycerate to 3-phosphoglycerate.
    [Show full text]